By Jason Derry --
MedImmune, Inc. and Biowa,
Inc. have announced a licensing and collaboration deal relating to development and
commercialization of therapies for inflammatory diseases. In particular, the agreement relates to
treatments that target interleukin-5 receptor. The companies have indicated that the initial focus will be on a
monoclonal antibody, BIW-8405, which is in Phase I clinical trials with asthma
patients. BIW-8405 is a humanized
monoclonal antibody that binds to the IL-5 receptor. Biowa has developed the antibody using its
POTELLIGENT® technology.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments